Invivyd Q2 Loss Widens; Going Concern Doubt and Nasdaq Delisting Notice Disclosed
IVVD sits 37% above its 52-week low of $0.483.
Summary
Invivyd's Q2 loss widened to $44.4M, and the 10-Q discloses going concern doubt, a Nasdaq delisting notice, and the upcoming loss of its only authorized product's EUA.
Key Events · Earnings and Guidance · IVVD
-
Q2 Net Loss Misses Estimates
Net loss of $44.4 million, or $0.14 per share, versus consensus of $0.11 per share. Revenue was $14.3 million, up 21% year-over-year.
-
Going Concern Doubt
Management concluded substantial doubt about ability to continue as a going concern, with cash and cash equivalents of $160.1 million insufficient to fund operations beyond one year from the filing date.
-
Nasdaq Delisting Notice
Received July 23, 2026, for closing bid price below $1.00 for 30 consecutive business days. Company has until January 19, 2027 to regain compliance.
-
PEMGARDA EUA Termination
HHS declaration termination will end PEMGARDA's emergency use authorization on June 29, 2027, eliminating the company's only authorized product revenue unless full approval is obtained.
Analysis · IVVD · Life Sciences
Invivyd reported a Q2 net loss of $44.4 million, missing consensus, and disclosed substantial doubt about its ability to continue as a going concern with less than one year of cash runway. The company also revealed a Nasdaq delisting notice received July 23, 2026, and the termination of its PEMGARDA EUA effective June 29, 2027. These are critical survival risks for a company with a market cap around $202 million.
At the time of this filing, IVVD was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $202M. The 52-week trading range was $0.48 to $3.07. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.